Developers should fess up about drug trial failures, researchers say

Naturally, drug researchers like to tout their victories and downplay their failures. But there are ramifications of not reporting results of experiments that go poorly, and two academics recently took on the issue in an a Science Translational Medicine article that says "translational medicine cannot approach its full potential if negative drug developments are unpublished," as Pharmalot's Ed Silverman cited in his interview with one of the authors. Michael Rogawski, chair of the department of neurology at UC Davis School of Medicine, talks to Silverman about his efforts to get developers to publish data they might rather keep under wraps. Interview

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.